Friday, February 2, 2024

Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders

  (BUSINESS WIRE) -- Sirius Therapeutics, announced it has dosed the first subject in a Phase 1, first-in-human clinical trial in Australia of SRSD107 on January 30th 2024, its next generation siRNA therapeutic targeting coagulation Factor XI (FXI), for the prevention and treatment of thromboembolic disorders. SRSD107 is the second clinical candidate in the company’s portfolio of next generation siRNA therapeutics to treat cardiovascular diseases. The company recently began clinical trials of SRSD101 in China for the treatment of dyslipidemia following IND clearance from the China National Medical Products Administration.

“This trial is based on in vivo studies that demonstrated a nearly 100% reduction of FXI levels for up to 6 months, without bleeding events, after a single subcutaneous dose,” said Dr. Qunsheng Ji, Sirius Therapeutics’ Chief Executive Officer. “The trial will provide an opportunity to evaluate SRSD107’s potential as a differentiated therapeutic for these common disorders globally.”

The SRSD107 Phase 1 study, which is being conducted in healthy volunteers in Australia, will evaluate SRSD107’s safety, tolerability, pharmacokinetics, and pharmacodynamics at single ascending doses and multiple ascending doses.


About Thromboembolic Disorders

Thrombosis, or blood clot formation, is the common underlying mechanism of most cases of myocardial infarction, ischemic stroke, and venous thromboembolism. According to a study in The Lancet of regional and global mortality, thromboembolic disorders are estimated to cause 1 in 4 deaths worldwide1.


About SRSD107

SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA). Developed by Sirius Therapeutics, SRSD107 specifically targets coagulation factor XI (FXI) mRNA and inhibits FXI protein expression, thereby blocking the intrinsic coagulation pathway and promoting anticoagulant/anti-thrombotic effects. SRSD107 has been engineered for the potential to enable once or twice-a-year dosing.


About Sirius Therapeutics

Sirius is an innovative, clinical stage biotech company developing next generation siRNA therapy for global markets. We are dedicated to discovering and developing new treatment options for cardiovascular disease patients. Our most advanced products are SRSD107 for the treatment of thromboembolic disorders, and SRSD101 for the treatment of dyslipidemia. Founded in 2021 by a world-class leadership team and investors, Sirius has established an innovative discovery center in the United States and translational medicine center in China. Sirius has raised nearly US$100 million funding to date from OrbiMed, Creacion Ventures, Hankang Capital, Delos Capital, and the leadership team.


[1] Lozano R, Naghavi M, Foreman K, et al. Lancet. 2012;380, 2095-1128.



View source version on businesswire.com: https://www.businesswire.com/news/home/20240201912539/en/



Permalink

https://www.aetoswire.com/en/news/0202202437421

Contacts

info@siriusrna.com


Official Website:

www.siriusrna.com

Takeda Announces Chief Financial Officer Succession

 OSAKA, Japan & CAMBRIDGE, Mass. - Thursday, 01. February 2024 AETOSWire


(BUSINESS WIRE) -- Takeda (TOKYO:4502/NYSE:TAK) today announced that Costa Saroukos, chief financial officer, has decided to leave Takeda to return to his home-country of Australia to be closer to family. Mr. Saroukos will step down as CFO, effective April 1, 2024 and will remain with the company as a board director until June 28, 2024. Milano Furuta, president of Takeda’s Japan Pharma Business Unit (JPBU), will succeed Mr. Saroukos, effective April 1, 2024. Mr. Furuta will report to Christophe Weber, president & CEO, and will be based in Tokyo, Japan. As CFO, Mr. Furuta will be proposed to the board of directors as a candidate for election to the board.


Christophe Weber commented: “On behalf of Takeda’s executive team and board of directors, I would like to thank Costa for his outstanding contributions and leadership. He has been a key driver of Takeda’s transformation and a trusted advisor to me and the board. He has also built a strong finance function and culture that will serve Takeda well for years to come. I wish Costa all the best as he returns to his home country to be closer to his family.”


Mr. Saroukos has played a pivotal role in Takeda’s transformation into a global biopharmaceutical company. His leadership during the acquisition and integration of Shire PLC., the largest-ever overseas acquisition by a Japanese company, was a critical factor in the deal’s success, and his financial stewardship has helped position the company for a renewed focus on growth investment and shareholder returns. He joined Takeda in 2015 as the CFO of the EUCAN [Europe and Canada] Business Unit and was appointed global CFO in April 2018.


Prior to joining Takeda in 2010, Mr. Furuta worked as an equity research analyst at an investment management firm in the United States. Mr. Furuta began his career in 2000 in banking and private equity investment in Japan, where he was involved with several types of financial transactions, including leveraged buyouts and debt restructuring. Before becoming JPBU president, Mr. Furuta served as corporate strategy officer and chief of staff at Takeda, and has held multiple leadership roles with the company around the world. Mr. Furuta holds an MBA from The Wharton School of the University of Pennsylvania and a bachelor’s degree in international affairs from Hitotsubashi University in Japan.


“It gives me great confidence to know that Milano, a long-time Takeda colleague, is stepping into this role,” said Mr. Weber. “Milano’s global experience and exceptional leadership qualities make him well-equipped to lead our talented finance organization. I look forward to working with Milano more closely to deliver on our commitment to investing in growth and shareholder returns.”


“It has been an honor to serve at Takeda and witness the positive impact we’ve made in the lives of patients. I am immensely proud of our successful transformation into a truly global biopharmaceutical company with a well-managed debt profile, robust cash flow and a long runway of profitable growth ahead. After 20 years working outside of Australia, I’m now looking forward to returning home to be closer to family. I’ve had the pleasure of working closely with Milano as a member of the Takeda Executive Team and I’m fully confident that his experience, financial background and strong leadership capabilities will help to ensure that Takeda remains focused on delivering on its commitments to shareholders,” said Costa Saroukos.


“I am honored and excited to take on the role of CFO of Takeda. I wish Costa all the best on his return to Australia and I look forward to building on his legacy and contributing to Takeda as a global, values-based, R&D-driven biopharmaceutical leader,” said Milano Furuta.


About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.


Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.


Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); the extent to which our internal energy conservation measures and future advancements in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas emissions; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this report or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this report may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20240131495750/en/



Permalink

https://aetoswire.com/en/news/0102202437399

Contacts

Global Media

Brendan Jennings

brendan.jennings@takeda.com


 

Thursday, February 1, 2024

China and Global Cement Agreement on Low Carbon Future

 BEIJING - Thursday, 01. February 2024


Milestone partnership launched to deliver sustainability of world’s essential material


(BUSINESS WIRE) -- The two leading representative bodies of the global cement industry have signed a milestone agreement to help accelerate decarbonisation of the sector across the world. China Cement Association (CCA), which represents more than 50% of the world’s cement production and the Global Cement and Concrete Association, whose members account for 80% of cement production capacity outside of China, have signed a historic partnership pledge.


The pledge includes an agreement to work together on sustainability, and the low-carbon development of the cement and concrete industry. Concrete is the world’s most used material on earth after water and cement is the key binding in concrete, and which accounts for around 7% of global CO2 emissions.


The historic agreement will also see the development, and launch later this year, of a whole value chain China Cement Carbon Neutrality Roadmap which will set out a commitment and pathway to fully decarbonise the cement industry in China. The GCCA, having launched a global net zero roadmap in 2021, will assist with its development alongside Sinoma International Engineering Co Ltd (Sinoma), the world’s largest cement technology and equipment company, and the European Cement Research Academy (ECRA) who will also provide technical input.


Launching the agreement at a signing ceremony in Beijing, Mr. Kong Xiangzhong, Executive President of CCA said: “This important agreement marks a win-win cooperation, and shows where we can collaborate effectively to bring insights, technical know-how and greater focus to our shared decarbonisation mission. I am sure this will create a mutually beneficial and long-term partnership that will be crucial in building a more sustainable world.”


Thomas Guillot, GCCA CEO said: “The world needs leadership and collaboration like never before, especially on addressing the key issue of our time, climate change. This agreement between the China industry and the global industry is a signal to the world that we stand ready to deliver the essential decarbonised building materials that our planet needs. Cement and concrete enable the key infrastructure, thriving and resilient communities, clean water, safe homes and the shift to clean energy that are essential to a future sustainable world.”


The agreement formally covers the next three years of co-operation and provides a platform for wider communication and exchange.


Thomas Guillot added: “Working with our new partners in China means our net zero focus and our action every day is now a truly global mission.”


About the China Cement Association – CCA

China Cement Association was established in Beijing in 1987. As one of the social organizations registered by the Ministry of Civil Affairs with independent legal personality, CCA is a national, non-profit industry social organization voluntarily formed by cement manufacturers, research institutes, colleges and universities, social organizations, and companies related to the cement industry nationwide. CCA commits to serve the industry, safeguard the legitimate rights and interests of its members, assist the government in jointly maintaining a fair competition market as the bridge between the government and enterprises, and promote the green, low-carbon and high-quality development of China cement industry with the leading, coordinating and service role.


About the Global Cement and Concrete Association - GCCA

The GCCA is a CEO led industry initiative that was set up in 2018 with headquarter stationed in London. It is the trusted, authoritative platform and voice for the cement and concrete sector across the world.


The GCCA and its members account for 80% of global cement production capacity outside of China, as well as a growing number of Chinese manufacturers. Member companies have committed to reducing and ultimately eliminating CO2 emissions in concrete, which currently account for around 7% globally, through implementation of the GCCA’s Concrete Future 2050 Net Zero Roadmap – the first heavy industry to set out such a detailed plan.


Together, GCCA is committed to building a bright, resilient and sustainable concrete future for the industry and for the world.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20240201041779/en/



Permalink

https://www.aetoswire.com/en/news/0102202437406

Contacts

For further details or interview requests, please contact:

Simon Thomson, Head of Media, GCCA

simon.thomson@gccassociation.org

+44 7380 972282


 

Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products

 OSAKA, Japan & CAMBRIDGE, Mass. - Thursday, 01. February 2024


    Two New U.S. FDA Approvals in FY2023 Q3: FRUZAQLA for Adults With Previously Treated Metastatic Colorectal Cancer and ADZYNMA for Ultra-Rare Blood Clotting Disorder cTTP
    Strong Commercial Execution Maximizing Value of Existing Portfolio:

    ENTYVIO® Pen Launched in U.S. for Ulcerative Colitis; U.S. FDA Approval Decision on Crohn’s Disease Filing Expected in early FY2024
    QDENGA ® Dengue Vaccine Now Launched in 21 Countries
    LIVTENCITY ® Approved in China for Refractory Post-Transplant CMV

    Revenue Growth of +4.6% at Actual Exchange Rate (AER); Flat at Constant Exchange Rate (CER)
    Core Operating Profit Change of -12.7% at CER, Reflecting Generic Impact, Lower Coronavirus Vaccines Revenue and Increased Investment in R&D and Data, Digital & Technology
    Life-Cycle Management Approvals for HYQVIA® and GAMMAGARD LIQUID® in January Support Forward Momentum of Growth & Launch Products
    Confirms Full-Year Management Guidance

(BUSINESS WIRE /AETOSWire)-- Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the third quarter of fiscal year 2023 (period ended December 31, 2023). With year-to-date strong momentum in its Growth & Launch Products (+12.7% at CER) offsetting the significant revenue impact of generic entrants, Takeda remains on track towards its full-year Management Guidance.

Takeda chief financial officer, Costa Saroukos, commented:

“In FY2023 Q3 we made further progress in our vision to discover and deliver life-transforming treatments, receiving two new U.S. FDA approvals and broadening the reach of our existing portfolio with multiple life-cycle management approvals for our Growth & Launch Products.

“We remain on track towards our full-year Management Guidance at CER, reflecting significant generic impact, lower coronavirus vaccines revenue and investment in R&D and data, digital and technology to secure our long-term competitiveness, as well as continued strong momentum in our Growth & Launch Products.

“We continue to improve our debt profile with 100% of our debt now at fixed interest rates averaging 1.6%, and our financial foundation remains strong as we enter the fourth quarter of FY2023.”

FINANCIAL HIGHLIGHTS

Results for FY2023 Q3 YTD Ended December 31, 2023

 

(Billion yen,
except
percentages and
per share
amounts)
    

REPORTED
    

 

CORE(c)

 

(Non-IFRS)(a)

 

FY2023 Q3 YTD
    

vs. PRIOR YEAR

(Actual % change)
    

FY2023 Q3 YTD
    

vs. PRIOR YEAR

(Actual % change)
    

vs. PRIOR YEAR

(CER % change(d))

Revenue
    

3,212.9
    

+4.6%
    

3,212.9
    

+4.6%
    

+0.0%

Operating Profit
    

224.1
    

-44.2%
    

865.6
    

-9.3%
    

-12.7%

Margin
    

7.0%
    

-6.1pp
    

26.9%
    

-4.1pp
    

 

Net Profit
    

147.1
    

-48.6%
    

643.6
    

-9.0%
    

-12.2%

EPS (yen)
    

94
    

-48.9%
    

412
    

-9.7%
    

-12.9%

Operating Cash Flow
    

437.8
    

-36.0%
    

 
    

 

 

Free Cash Flow
(Non-IFRS)(a)(b)

 
    

36.3
    

-93.8%
    

 
    

 

 

Further information regarding certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at https://www.takeda.com/investors/financial-results/quarterly-results/ .

(b) We define Free Cash Flow as cash flows from operating activities, subtracting acquisition of property, plant and equipment (“PP&E”), intangible assets and investments as well as removing any other cash that is not available to Takeda’s immediate or general business use, and adding proceeds from sales of PP&E, as well as from sales of investments and businesses, net of cash and cash equivalents divested.

(c) Core results adjust our reported results calculated and presented pursuant to IFRS to exclude the effect of items unrelated to Takeda’s core operations, such as, to the extent applicable for each line item, non-recurring items, purchase accounting effects and transaction related costs, as well as amortization and impairment of intangible assets and other operating income and expenses.

(d) CER (Constant Exchange Rate) change eliminates the effect of foreign exchange rates from year-over-year comparisons by translating Reported or Core results for the current period using corresponding exchange rates in the same period of the previous fiscal year.

 

 

 

FY2023 OUTLOOK

On track towards full-year FY2023 Management Guidance

(Billion yen except per share amounts)
    

FY2023

FORECAST
(Unchanged from

October 2023)
    

FY2023

MANAGEMENT GUIDANCE

Core Change at CER (Non-IFRS)
(Unchanged from May 2023)

Revenue
    

3,980.0
    

 

Core Revenue
    

3,980.0
    

Low-single-digit % decline

Reported Operating Profit
    

225.0
    

 

Core Operating Profit
    

1,015.0
    

Low-10s % decline

Reported Net Profit
    

93.0
    

 

Reported EPS (yen)
    

59
    

 

Core EPS (yen)
    

447
    

Low-20s % decline

Free Cash Flow*
    

400.0-500.0
    

 

Annual Dividend per Share (yen)
    

188
    

 

*Free Cash Flow forecast reflects expenditures related to the acquisition of TAK-279 from Nimbus and in-licensing of FRUZAQLA (fruquintinib) from HUTCHMED.

Additional Information About Takeda’s FY2023 Q3 Earnings Results
For more details on Takeda’s FY2023 Q3 results and other financial information, including key assumptions in FY2023 forecast and management guidance, please visit: https://www.takeda.com/investors/financial-results/quarterly-results/

For more information on Takeda’s commercial progress across the five key business areas and pipeline updates, please visit: https://takeda.info/qr2023_q3_qfr_en

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); the extent to which our internal energy conservation measures and future advancements in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas emissions; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this report or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this report may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Financial information and Certain Non-IFRS Financial Measures
Takeda’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”).

This press release and materials distributed in connection with this press release include certain financial measures not presented in accordance with IFRS, such as Core Revenue, Core Operating Profit, Core Net Profit, Core EPS, Constant Exchange Rate (“CER”) change, Net Debt, EBITDA, Adjusted EBITDA and Free Cash Flow. Takeda’s management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this presentation. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. By including these non-IFRS measures, management intends to provide investors with additional information to further analyze Takeda’s performance and core results, including when controlling for the effect of fluctuations in exchange rates. Takeda’s non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as “reported” measures). Investors are encouraged to review the definitions and reconciliations of non-IFRS financial measures to their most directly comparable IFRS measures, which are in the financial appendix at the end of Takeda's FY2023 Q3 investor presentation (available at takeda.com/investors/financial-results/quarterly-results/).

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

Please refer to slide 17 of Takeda’s FY2023 Q3 investor presentation (available at takeda.com/investors/financial-results/quarterly-results/) for the definition of Growth & Launch Products.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240131987348/en/

 

Permalink
https://www.aetoswire.com/en/news/1022024373988

Contacts

Investor Relations
Christopher O’Reilly
Christopher.oreilly@takeda.com
+81 (0) 3-3278-2543

Media Relations
Brendan Jennings
Brendan.jennings@takeda.com
+81 (0) 3-3278-2111

Kinaxis Inc. to Host Fourth Quarter 2023 Financial Results Conference Call on February 29, 2024

 OTTAWA, Ontario - Thursday, 01. February 2024 AETOSWire Print 


(BUSINESS WIRE) -- Kinaxis® (TSX:KXS), the leading supply chain management platform, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2023. The call will be hosted on Thursday, February 29 at 8:30 a.m. Eastern Time by John Sicard, Chief Executive Officer, and Blaine Fitzgerald, Chief Financial Officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year-end after the close of markets on Wednesday, February 28, 2024.


CONFERENCE CALL DETAILS


DATE:


 

Thursday, February 29, 2024


TIME:


 

8:30 a.m. Eastern Time


CALL REGISTRATION:


 

https://registrations.events/direct/Q4I914168


WEBCAST:


 

https://events.q4inc.com/attendee/409673001 (available for three months)


REPLAY:


 

(800)-770-2030 or (609) 800-9909


 


 

Available through March 14, 2024


 


 

Reference number: 91416


Advance call registration


Investors and participants must register in advance for the call. After registering, instructions on how to join the call will automatically be emailed, including dial-in information as well as a unique pincode. At the time of the call, registered participants will dial in using the numbers from the confirmation email, and upon entering their unique pincode, will be entered directly into the conference. It is recommended that you register for the call at least 15 minutes prior to the start time.


About Kinaxis


Kinaxis is a global leader in modern supply chain management. We serve supply chains and the people who manage them in service of humanity. Our software is trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. We combine our patented concurrency technique with a human-centered approach to AI to empower businesses of all sizes to orchestrate their end-to-end supply chain network, from multi-year strategic planning through down-to-the-second execution and last-mile delivery. For more news and information, please visit kinaxis.com or follow us on LinkedIn.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20240201774521/en/



Permalink

https://www.aetoswire.com/en/news/0102202437403

Contacts

Media Relations

Jaime Cook | Kinaxis

jcook@kinaxis.com

289-552-4640


Investor Relations

Rick Wadsworth | Kinaxis

rwadsworth@kinaxis.com

613-907-7613

Rimini Street Appoints Gertrude Van Horn as CIO

 Former Rimini Street client and award-winning IT executive brings decades of experience and success as an innovative leader of complex, global organizations


(BUSINESS WIRE) -- Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products, and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, today announced the appointment of Gertrude 'Trude' Van Horn as executive vice president and chief information officer. As the CIO of Rimini Street, Van Horn is responsible for the vision, direction, and expert execution of the Global IT and Security department's growth strategy.


Van Horn is an accomplished and celebrated CIO with decades of global IT leadership experience in public and private companies across diverse industries, including financial services, manufacturing, and retail. Van Horn's extensive technology expertise includes senior roles at American Express, JP Morgan, Jo-Ann Stores, Office Depot, Haggar Clothing Company, and Victoria's Secret.


From a Rimini Street Client and Advocate to Rimini Street CIO


Prior to her appointment as CIO, Van Horn served as senior vice president and CIO at NCH Corporation where she led pivotal initiatives to revamp their IT infrastructure, refine business processes, and champion innovation across the 100+ year-old, billion-dollar organization.


“I was first introduced to Rimini Street in 2013 and was immediately impressed by their expertise, quality resources, and commitment to NCH’s success and satisfaction. Rimini Street was an excellent partner for many years, and I am delighted to make the move from being a client to now taking on this new challenge,” said Van Horn.


She added, “As the CIO of Rimini Street, I am doubly excited to share my experience with other business leaders looking for a true IT partner to help them achieve their growth and profitability goals.”


Leading Rimini Street's Next Generation IT Vision


“Without a doubt, an exceptional IT vision coupled with brilliant execution is imperative to the company’s success in both capability and speed,” said Rimini Street president and CEO Seth Ravin. “Trude's wealth of experience and proven track record in leading technology transformations are invaluable assets for our organization.”


About Rimini Street, Inc.


Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a global provider of end-to-end enterprise software support, products and services, the leading third-party support provider for Oracle and SAP software and a Salesforce and AWS partner. The Company has operations globally and offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize enterprise application, database, and technology software, and enables clients to achieve better business outcomes, significantly reduce costs and reallocate resources for innovation. To date, over 5,300 Fortune 500, Fortune Global 100, midmarket, public sector, and other organizations from a broad range of industries have relied on Rimini Street as their trusted enterprise software solutions provider. To learn more, please visit riministreet.com, and connect with Rimini Street on Twitter, Instagram, Facebook and LinkedIn. (IR-RMNI)


Forward-Looking Statements


Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "anticipate," "believe," "continue," "could," "currently," "estimate," "expect," "future," "intend," "may," "might," "outlook," "plan," "possible," "potential," "predict," "project," "seem," "seek," "should," "will," "would" or other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street's business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, adverse developments in and costs associated with defending pending litigation or any new litigation, including the disposition of pending motions to appeal and any new claims; additional expenses to be incurred in order to comply with injunctions against certain of our business practices and the impact on future period revenue and costs; changes in the business environment in which Rimini Street operates, including the impact of any recessionary economic trends and changes in foreign exchange rates, as well as general financial, economic, regulatory and political conditions affecting the industry in which we operate and the industries in which our clients operate; the evolution of the enterprise software management and support landscape and our ability to attract and retain clients and further penetrate our client base; significant competition in the software support services industry; customer adoption of our expanded portfolio of products and services and products and services we expect to introduce; our ability to sustain or achieve revenue growth or profitability, manage our cost of revenue and accurately forecast revenue; estimates of our total addressable market and expectations of client savings relative to use of other providers; variability of timing in our sales cycle; risks relating to retention rates, including our ability to accurately predict retention rates; the loss of one or more members of our management team; our ability to attract and retain qualified employees and key personnel; challenges of managing growth profitably; our need and ability to raise additional equity or debt financing on favorable terms and our ability to generate cash flows from operations to help fund increased investment in our growth; the impact of environmental, social and governance (ESG) matters; risks associated with global operations; our ability to prevent unauthorized access to our information technology systems and other cybersecurity threats, protect the confidential information of our employees and clients and comply with privacy regulations; our ability to maintain an effective system of internal control over financial reporting; our ability to maintain, protect and enhance our brand and intellectual property; changes in laws and regulations, including changes in tax laws or unfavorable outcomes of tax positions we take, or a failure by us to establish adequate tax reserves; our credit facility’s ongoing debt service obligations and financial and operational covenants on our business and related interest rate risk, including uncertainty from the transition to SOFR or other interest rate benchmarks; the sufficiency of our cash and cash equivalents to meet our liquidity requirements; the amount and timing of repurchases, if any, under our stock repurchase program and our ability to enhance stockholder value through such program; uncertainty as to the long-term value of Rimini Street’s equity securities; catastrophic events that disrupt our business or that of our clients; and those discussed under the heading “Risk Factors” in Rimini Street’s Quarterly Report on Form 10-Q filed on November 1, 2023, and as updated from time to time by Rimini Street’s future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street's expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street's assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street's assessments as of any date subsequent to the date of this communication.


© 2024 Rimini Street, Inc. All rights reserved. "Rimini Street" is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20240201044861/en/



Permalink

https://www.aetoswire.com/en/news/0102202437409

Contacts

Janet Ravin

VP, Global Communications

Rimini Street, Inc.

+1 702 285-3532

pr@riministreet.com

AIT Worldwide Logistics Acquires Global Transport Solutions Group

ITASCA, Ill. - Thursday, 01. February 2024


European-based marine spare parts logistics specialist with more than 600 teammates in 11 countries is AIT’s most significant acquisition to date


(BUSINESS WIRE) -- AIT Worldwide Logistics, one of the world’s leaders in global supply chain solutions, has acquired Global Transport Solutions Group (GTS), a prominent international freight forwarder specializing in time-critical marine spare parts logistics.


Headquartered in the Netherlands, GTS and its more than 600 teammates across 16 locations in Asia, Europe, the Middle East and North America, serve over 2,000 ports around the world. The GTS network also includes nine consolidation hubs totaling more than 45,000 square meters of warehouse space.


AIT Chairman and Chief Executive Officer, Vaughn Moore, said, “I’d like to welcome our new GTS teammates to the global AIT network. This is the largest acquisition in our company’s history and GTS’ marine spare parts business is an excellent complement to AIT’s time-critical supply chain solutions.”


The company’s business is divided into two sub-brands: Marinetrans (founded in 1991), excelling in “door-to-deck” spare parts logistics for ship owners and managers, and Best Global Logistics (founded in 2007), providing time-critical solutions and general forwarding for other industries, including life sciences shippers.


According to AIT’s Chief Business Officer, Greg Weigel, the acquisition provides the company with new geographic presence in Greece, Japan and the Nordic region while adding significant capacity and subject matter expertise to existing AIT networks in China, the Netherlands and Singapore. The deal also provides a strong foundation to expand GTS’ world-class marine spare parts solutions via AIT’s expansive global freight network.


“The acquisition of GTS creates an incredible portfolio of solutions serving the maritime industry with delivery of time-critical spare parts across all geographies. This is a perfect complement to AIT’s vertical strategies focused on expedited mission-critical services like our Critical Solutions Group, government and AOG team, and Life Sciences Division,” Weigel said. “We plan to rapidly invest and expand GTS’ North American operations by capitalizing on AIT’s robust salesforce in the United States and offering maritime customers a world-class spare parts logistics solution in every port.”


AIT President and Chief Operating Officer, Keith Tholan, noted that the GTS core values – customer first, operational excellence, and partnership and collaboration – closely mirror AIT’s core values.


“We are delighted to welcome GTS teammates to AIT,” Tholan said. “Their deep marine logistics expertise and three decades of proven on-time performance in a very demanding segment will complement the diverse solutions we offer across our vertical sector strategy. We also expect our best-in-class global air freight procurement will instantly benefit their time-critical operations.”


According to GTS co-CEO John Burgstra, the acquisition is an opportunity for GTS to further expand their worldwide operations.


“We aim to provide our clients an unrivaled experience when it comes to global visibility, transparency and on-time performance, fully unburdening them of the required logistical handling of their vessels’ spare parts,” he said. “We are excited about becoming part of a larger group and the global development opportunities this acquisition will provide for our teammates.”


“Because of the highly fragmented and international nature of our clients’ requirements, they need a trusted partner with a vetted and effective global network,” added GTS co-CEO Vegard Prytz. “GTS will gain enormous benefits from leveraging the global AIT infrastructure, creating an even more integrated and seamless solution for clients around the world.”


Terms of AIT’s agreement to acquire Global Transport Solutions Group have not been disclosed.


About AIT Worldwide Logistics


AIT Worldwide Logistics is a global freight forwarder that helps companies grow by expanding access to markets all over the world where they can sell and/or procure their raw materials, components and finished goods. For more than 40 years, the Chicago-based supply chain solutions leader has relied on a consultative approach to build a global network and trusted partnerships in nearly every industry, including aerospace, automotive, consumer retail, food, government, healthcare, high-tech, industrial and life sciences. Backed by scalable, user-friendly technology, AIT’s flexible business model customizes door-to-door deliveries via sea, air, ground and rail — on time and on budget. With expert teammates staffing more than 130 worldwide locations in Asia, Europe and North America, AIT’s full-service options also include customs clearance, warehouse management and white glove services. Learn more at www.aitworldwide.com.


Our Mission


At AIT, we vigorously seek opportunities to earn our customers’ trust by delivering exceptional worldwide logistics solutions while passionately valuing our co-workers, partners and communities.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20240201861788/en/



Permalink

https://www.aetoswire.com/en/news/0102202437404

Contacts

Matt Sanders

Public Relations Manager

+1 (630) 766-8300

msanders@aitworldwide.com


AIT Worldwide Logistics, Inc.

800-669-4AIT (4248)

www.aitworldwide.com